$Theratechnologies (THTX.US)$ NEWS Theratechnologies’ Sudoce...
NEWS
Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term Efficacy and Manageable Safety Profile in Patients with Solid Tumors
Theratechnologies announced promising Phase 1 data for its investigational drug, sudocetaxel zendusortide, at the 2024 ASCO annual meeting.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a unique, multimodal mechanism of action and a favorable safety profile. Notably, 44% of the female cancer patients achieved a clinical benefit rate.
The company is now moving into Part 3 of the Phase 1 trial, focusing on dose optimization.
The drug showed long-term disease stabilization in patients with solid tumors, lasting up to 45 weeks even after treatment ceased.
The study highlighted a unique, multimodal mechanism of action and a favorable safety profile. Notably, 44% of the female cancer patients achieved a clinical benefit rate.
The company is now moving into Part 3 of the Phase 1 trial, focusing on dose optimization.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1076Followers
68Following
7415Visitors
Follow